Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Metrics to compare | 430 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship430PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −0.7x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 1.5x | 2.6x | |
Price / LTM Sales | 0.0x | 1.4x | 3.3x | |
Upside (Analyst Target) | 0.0% | 315.3% | 43.4% | |
Fair Value Upside | Unlock | −4.7% | 7.1% | Unlock |